HOME >> BIOLOGY >> NEWS
Can heart failure impair thinking?

Bethesda, MD Heart failure (HF) is a clinical syndrome characterized by distinctive symptoms and signs resulting from disturbances in cardiac output or from increased venous pressure. According to the National Heart, Lung and Blood Institute, up to three million Americans have heart failure, with 400,000 new cases being diagnosed each year. It is a condition that is slightly more common among men than women and is twice as common among blacks compared to whites.

Background

HF is among the most serious symptom of heart disease, killing about two-thirds of all patients within five years of diagnosis. Patients are treated with mediations such as ACE inhibitors and digitalis so that the heart does not have to work so strenuously to pump blood. HF has other effects as well.

High sympathetic and decreased parasympathetic activities are characteristic of HF and are manifested as blunted baroreceptor activity, diminished parasympathetic effects on the sinoatrial node, increased norepinephrine, decreased heart rate variability, and diminished responsiveness and number of 1-receptors. These characteristics may result from peripheral or central aberrations. The parasympathetic alterations may derive from reduced cardiac muscarinic receptors; however, they also may result from central nervous system (CNS) dysfunction.

The cognitive deficits also suggest CNS dysfunction, possibly developing from ischemic damage as a consequence of HF. The principal neurological deficit of HF patients appears to be delayed recall. This memory dysfunction suggests specific neural damage related to the hippocampus or frontal lobe or associated circuitry, rather than generalized deficits over the entire brain.

Approximately one-half of chronic HF patients exhibit obstructive sleep apnea (OSA) or Cheyne-Stokes breathing during sleep. OSA cases show significant gray matter loss in cerebellar, insular, and cortical areas, which may contribute to abe
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
23-Sep-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
2. Screen siblings, parents of infants with severe heart abnormalities
3. Recent evolution at a single gene may have brought down heart disease risk in some human groups
4. How do you mend a broken heart?
5. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Putting energy into heart protection
8. Rare mutations can significantly increase risk factor for heart disease
9. Smart gene therapy protects against damage from heart attack
10. University of Pittsburgh medical center among first to implant heart assist device
11. Reading hexametric rhyme supports cardiac synchronization, especially after a heart attack

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Can heart failure impair thinking

(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: